Product Description
Our technology, that have originated in the University of Pennsylvania, is a revolutionary novel type of autologous combinational cell therapy enhancing efficacy of therapeutic antibodies in solid and liquid tumors. It is based on newly discovered Hybrid neutrophils possessing unique composite features of cytotoxic and antigen-presenting cells (APCs). Hybrid Neutrophils not only kill antibody-opsonized tumor cells with similar efficacy as NK cells, but also possess the ability to uptake tumor antigens and efficiently cross present them to CD8+ T-cells generating strong tumor-specific immune response in the patient. (Sourced from: https://www.linkedin.com/company/hybrid-biotherapeutics-inc/)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hybrid Bio
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|